Universal Time: 01:18  |  Local Time: 01:18 (0h GMT)
Select your timezone:

Sun Sep 13

23:30 - 00:15 Oral Abstracts Session: Kidney Transplantation: Biomarkers
210.1 Diagnostic tests for delayed graft function: A systematic review
Christina Lai, Australia
210.2 Integrative analysis of prognostic biomarkers for acute rejection in kidney transplant recipients
Yue Cao, Australia
210.3 Assessment of the usefulness of acute rejection specific transcriptomic signatures in a prospective kidney transplantation cohort
Su Woong Jung, Korea
210.4 The clinical utility of preformed C1q-binding donor-specific HLA antibodies in kidney transplantation
Sua Lee, Korea
23:30 - 00:15 Oral Abstracts Session: Innate and Adaptive Immunity
211.1 Gasdermin-D mutation is protective against renal ischemia reperfusion injury
Jennifer Li, Australia
211.5 (P-2.74 in Journal) Oral administration of nano-sized silicon particles attenuates oxidative stress and ischemia-reperfusion injury in a rat model: A novel hydrogen administration method
Masataka Kawamura, Japan
211.3 Modulation of the IL-33/ST2 axis for regulatory T cell therapy in transplantation
Kento Kawai, United Kingdom
211.4 Development of fully differentiated pancreatic organoids from hiPSCs for type 1 diabetes cell therapy
Giuseppe Pettinato, United States
23:30 - 00:15 Oral Abstracts Session: Living Donor Liver Transplantation
212.1 Survival benefits of living donor liver transplant for hepatorenal syndrome candidates on waitlist
Tiffany Cho-Lam Wong, Hong Kong
212.2 Outcomes of robotic living donor right hepatectomy from 52 consecutive cases: Comparison with open and laparoscopy-assisted donor hepatectomy
Seoung Yoon Rho, Korea
212.3 Robotic living donor right hepatectomy: A current standardized procedure
Hyeo Seong Hwang, Korea
212.4 Demarcating the exact midplane of the liver using indocyanine green near-infrared fluorescence imaging during laparoscopic donor hepatectomy
Jeesun Kim, Korea
23:30 - 00:15 Oral Abstracts Session: Pancreas and Islet Abstract Session
213.2 A novel pre-vascularized tissue engineering chamber serves as a bio-artificial pancreas for an attractive site of allogenic and xenogeneic islet transplantation
Yanzhuo Liu, People's Republic of China
213.4 Pancreas rejection with hyperglycemia: Is it always too late?
Pablo Uva, Argentina
213.1 A pilot clinical trial outcome of biosafety system evaluation for PERV-C free porcine islet xenotransplantation based on principle of WHO “Changsha Communique”
Wei Wang, People's Republic of China
213.3 Islets engineered with CD47 innate immune checkpoint protein show enhanced engraftment following intraportal transplantation by mitigating instant blood mediated inflammatory reaction
Pradeep Shrestha, United States

Mon Sep 14

00:15 - 02:00 State-of-the-Art Session: Tissue-Resident Lymphocytes
220.1 Formation and plasticity of tissue resident memory populations in human allografts revealed by single cell analysis and serial TCR sequencing
Megan Sykes, United States
220.2 Antigen presentation by tissue resident APC
Adrian E. Morelli, United States
220.3 Reshaping T cell memory with lymphoablation
Anna Valujskikh, United States
07:30 - 08:15 Oral Abstracts Session: Immune Regulation and Outcomes
251.2 Discovery of pMHC epitopes for directly alloreactive T cells
Eric Taeyoung ES Son, Australia
251.3 The Prediction of Kidney Allograft Acute Rejection Based on Recipient Peripheral Blood Whole Transcriptome Profiling and Three mRNA Molecular Signatures
Liao Minxue, People's Republic of China
251.4 Myeloid derived suppressor cells (MDSC) in kidney recipients: Identification of CD25+eMDSC, and augmentation of monocytic-MDSC early after transplantation in patients later developing cancer
Alberto Utrero-Rico, Spain
251.1 Elucidating the role of hypoxia in regulatory T cell function
Marie Sion, United Kingdom
08:15 - 10:00 State-of-the-Art Session: Managing Immunosuppression When Things Go Wrong
261.1 Managing IS in recipients with a failing graft
Sangho Lee, Korea
261.3 Managing IS in recipients treated for malignancies
Daniel Seron, Spain
261.2 Managing IS in recipients with complex infections
Peter Chin-Hong, United States
13:00 - 14:30 Workshop Session: What is the Ideal Pig for Xenotransplantation? / Carl-Gustav Groth Xeno Prize
276.1 Are remaining xeno-antigens relevant?
Alfred Joseph Tector, United States
276.2 The ideal modified pig, how many genes are necessary?
Eckhard Wolf, Germany
276.3 Do we need to address p?hysiologic incompatibilities
David K. C. Cooper, United States
276.4 Xeno-organ growth: myth or reality?
Matthias Längin, Germany
276.5 Presentation of the Carl-Gustav Groth Xeno Prize to Joachim Hundrieser
Agnes Azimzadeh, United States
14:30 - 15:15 Oral Abstracts Session: Biomarkers and Omics
281.3 Single cell transcriptomic analysis for a better understanding of human CD8+ regulatory T cells
Céline Serazin, France
281.1 Transplantation of older organs transfers senescence
Jasper Iske, Germany
281.5 (P-2.125 in Journal) TCR repertoire sequencing of total T cells and circulating follicular helper T cells in kidney transplant recipients
Patricia Almendro Vázquez, Spain
281.2 Diagnosis of kidney transplant rejection by tracking donor-reactive T-cell clones in the post-transplant biopsy, blood and urine samples
Joseph R. Leventhal, United States
14:30 - 15:15 Oral Abstracts Session: Xenotransplantation Abstract Session
283.1 Worldwide first finalized study of preclinical life-supporting orthotopic pig-to-baboon cardiac xenotransplantation (XT): Constant reproducible 3-months-survival up to half a year meets the ISHLT guidelines for first clinical trials
Paolo Brenner, Germany
283.2 Prolonged survival and attenuated pulmonary vascular resistance rise in a multitransgenic pig ex vivo lung xenoperfusion model
Margaret Connolly, United States
283.3 Prolonged survival of genetically modified pig livers during machine perfusion with human blood
Taylor Coe, United States
283.4 Humanized von Willebrand factor reduces platelet sequestration in pig xenogeneic lung perfusion and pig-to-primate lung transplantation
Margaret Connolly, United States
15:15 - 17:00 State-of-the-Art Session: Kidney Transplantation: The borg and beyond
290.1 The repair shop: Our current opportunities in improving the quality of kidneys
Sarah Hosgood, United Kingdom
290.2 A reality check - kidney organoids: What to expect in the next 10 years
Benjamin Humphreys, United States
290.3 Artificial intelligence in renal transplantation: core concepts, examples, limits and perspectives
Olivier Niel, Luxembourg
22:00 - 23:30 Workshop Session: Cutting-Edge Issues in Peri-Transplant Management
301.2 Management of ABO incompatibility
Toru Ikegami, Japan
301.3 Management of pre-DSA and LCM positive
Jacqueline O'Leary, United States
301.1 Management of hepatitis C virus
Paul Kwo, United States
23:30 - 00:15 Oral Abstracts Session: Kidney Transplantation: Predicting allograft survival
310.2 Simultaneously detection of ddcfDNA in plasma and urine assist to determine the type of rejection in renal transplant patients
Dongrui Cheng, People's Republic of China
310.1 Advanced tertiary lymphoid tissues in protocol biopsies predict progressive graft dysfunction in kidney transplant recipients
Yu Ho Lee, Korea
310.3 Near-single-cell proteomicsprofiling of the proximal tubular and glomerulus of the normal human kidney
Tara Sigdel, United States
310.4 A personalised prediction model for allograft survival after kidney transplantation
Yunwei Zhang, Australia
23:30 - 00:15 Oral Abstracts Session: Malignancy and Long Term Outcomes after Liver Transplantation
311.2 Pregnancy outcomes in 331 female liver transplant recipients
Lisa Coscia, United States
311.3 CX3CL1/CX3CR1 axis facilitates recruitment of regulatory macrophages to promote tumor recurrence after liver transplantation for intrahepatic cholangiocarcinoma
Jiye Zhu, Hong Kong
311.4 (P-12.57 in Journal) Short- and long-term outcomes for ethnic minorities in the United States after liver transplantation: Factors associated with graft failure
Mohammad S Ali, United States
23:30 - 00:15 Oral Abstracts Session: Experimental and Preclinical Immunosuppression
312.2 Targeting inflammatory monocytes by immune-modifying nanoparticles prevents acute kidney allograft rejection
Christina Lai, Australia
312.4 ABO self-tolerance in a mouse model: Evidence of tolerance at B cell but not T cell level
Ibrahim Adam, Canada
312.1 Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage CSF (GM-CSF) administration enriches for highly suppressive CD4+CD45RA-Foxp3hi cells in leukapheresis products of rhesus monkeys
Kazuki Sasaki, United States
312.3 Carfilzomib and lulizumab-based desensitization prolongs allograft survival in sensitized non-human primates kidney transplantation model
Jean Kwun, United States
23:30 - 00:15 Oral Abstracts Session: Histocompatibility and Cancer Complications
314.1 Do we predict mismatches that induce de novo DSA or do we predict the ones that do not?
Vadim Jucaud, United States
314.2 HLA molecular mismatch analysis in patients receiving kidney and the hematopoietic stem / facilitating cell induction protocol
Anat Tambur, United States
314.3 Cancer risk in solid organ transplant recipients: A systematic review and meta-analysis
Zhenyu Huo, People's Republic of China
314.5 (P-11.126 in Journal) Relative survival in kidney transplant recipients with de-novo cancers vs non-transplant cancer patients: A population study 1980-2016
Nicole Louise De La Mata, Australia

Tue Sep 15

06:00 - 07:30 Workshop Session: Regulation of Xenotransplantation
341.4 Update on the Changsha Communiques
Wayne J. Hawthorne, Australia
341.2 Regulation in China
Shaoping Deng, People's Republic of China
341.1 Regulation in Korea
Ivo Kwon, Korea
341.3 Regulating Safety: what’s new?
Linda Scobie, United Kingdom
07:30 - 08:15 Oral Abstracts Session: Kidney Transplantation: Ischemia/reperfusion injury and long-term graft outcomes
350.1 Role of IL-6 and IL-17 mediated inflammation amplifier loop in Chronic Antibody-Mediated Rejection (CABMR)
Mantabya Kumar Singh, India
350.2 A biocompatible nanoparticle-based approach to inhibiting renal ischemia reperfusion injury in mice by blocking thrombospondin-1 activity
Tianmeng Sun, People's Republic of China
350.4 Impact of acute kidney injury on graft outcomes in deceased donor kidney transplantation: A nationwide registry-based matched cohort study in Korea
Jane Ha, Korea
350.5 (P-2.81 in Journal) A point mutation of SHROOM3 promotes CD206+ macrophage infiltration and kidney fibrosis after ischemia-reperfusion injury
Tianfeng Tang, People's Republic of China
08:15 - 10:00 State-of-the-Art Session: The Future is Now… Immune Regulation in Transplantation
360.1 The Regulation of Immune Tolerance by FOXP3 - basic
Ling Lu, People's Republic of China
360.2 Intragraft immune regulation protects transplants under sub-therapeutic immunosuppression
Paloma Riquelme, Germany
James Alexander Hutchinson, Germany
360.3 Clinical experience of Treg therapy
Fadi Issa, United Kingdom
14:30 - 15:15 Oral Abstracts Session: Immune Regulation and Tolerance I
381.4 Single cell immune profiling of human intestinal allografts reveals heterogeneity and alloreactivity of recipient resident memory T cells in association with graft outcomes
Jianing Fu, United States
381.1 Treg use the PD-1-PD-L1 axis for lymphatic transendothelial migration
Wenji Piao, United States
381.2 Donor liver plasmacytoid dendritic cells promote effector T cell exhaustion and augment Treg responses in mouse spontaneous liver transplant tolerance
Ryosuke Nakano, United States
381.3 Lymph node stromal laminin alpha 5 regulates adaptive immunity
Lushen Li, United States
14:30 - 15:15 Oral Abstracts Session: Stem Cell Transplantation and Xenotransplantation
384.2 Quantifying the immune response to tissue engineered extracellular matrix
Ryaan EL-Andari, Canada
384.1 Simple Limbal Epithelial Transplantation (SLET) in a patient with limbal stem cell deficiency
Dilek Dursun Altinors, Turkey
384.3 Successful long-term TMA- and rejection-free survival of a kidney xenograft with triple xenoantigen knockout plus insertion of multiple human transgenes
David Ma, United States
384.4 Evidence for GTKO/β4GalNT2KO pigs as the preferred organ-source for old world monkeys as a preclinical model of xenotransplantation instead of triple-knockout pigs
Takayuki Yamamoto, United States
15:15 - 17:00 State-of-the-Art Session: How to Deal with Hepatocellular Carcinoma
390.3 Post-LT: optimal immunosuppression and follow-up
Nancy Kwan Man, Hong Kong
390.1 Pre-LT: down-staging and optimal selection
Kim M. Olthoff, United States
390.2 Intra-LT: how to improve oncologic outcomes
Elizabeth A. Pomfret, United States
390.4 Liver Tx for cholangiocarcinoma
Julie K. Heimbach, United States
15:15 - 17:00 State-of-the-Art Session: Novel Insights in Allorecognition
391.3 Non-HLA allorecognition and graft loss
Roman Reindl-Schwaighofer, Austria
391.2 T-cell allorecognition
Gavin Pettigrew, United Kingdom
391.1 Innate allorecognition
Fadi G. Lakkis, United States
15:15 - 17:00 State-of-the-Art Session: VCA: Cutting Edge Advances and Applications
393.1 Calcineurin-free immunosuppression in VCA – Outcomes and opportunities
Linda C. Cendales, United States
393.2 Regenerative surgery – The new realm
Giuseppe Orlando, United States
393.3 Cell targeted nanoimaging for graft surveillance – Advances in solid organ and VCA applications
Jelena M. Janjic PhD, United States
393.4 Biomarker surrogates for immune monitoring of VCA
Helen Stark, United Kingdom
15:15 - 17:00 Workshop Session: Novel Strategies in Support to Hepatocyte Transplant
394.4 Human liver stem cell-derived extracellular vesicles
Giovanni Camussi, Italy
394.1 Hepatocyte transplantation overview
Anil Dhawan, United Kingdom
394.2 Hepatic spheroids
Volker Lauschke, Sweden
23:30 - 00:15 Oral Abstracts Session: Kidney Transplantation: Novel approaches to monitoring
410.1 (P-11.189 in the Journal) Reactivation of murine polyomavirus replication by renal ischemia-reperfusion injury and immunosuppression
Gang Huang, People's Republic of China
410.3 Analysis of the difference of the monitoring results of TCR high variable area in renal transplant recipients after treatment with different immune induction schemes
Tian Puxun, People's Republic of China
410.4 Novel human kidney cell subsets identified by Mux-Seq
Tara Sigdel, United States
23:30 - 00:15 Oral Abstracts Session: Cell and Novel Therapies
412.1 Human mesenchymal-stem-cells derived exosomes play important roles in enhancing CB-treg suvival and functional stability
Juan Zhang, People's Republic of China
412.3 Targeting CD4+ T cell metabolism provides an effective and age-specific immunosuppression
Yeqi Nian, People's Republic of China
412.2 Phase 2 study design evaluating efficacy, safety, pharmacokinetics and pharmacodynamics of the anti-CD40 monoclonal antibody CFZ533 (iscalimab) in de novo liver transplant recipients: The CONTRAIL I study
Björn Nashan, Germany
412.4 Long-term follow-up of a phase 2 clinical trial to induce tolerance in living donor renal transplant recipients
Joseph R. Leventhal, United States

Wed Sep 16

07:30 - 08:15 Oral Abstracts Session: Immune Regulation and Tolerance II
451.3 PD-L1 / PD-1 interactions are critical for tolerance induction in primed skin graft recipients following liver-directed MHC class I gene transfer
Mario L Leong, Australia
451.2 Identification and isolation of human HLADR+ CD27+ Treg as xeno-antigen Treg subset for xenotransplantation
Xiaoqian Ma, People's Republic of China
451.1 Transient antibody targeting of CD45RC to prevent the development of acute graft versus host diseases
Carole Guillonneau, France
451.4 CTLA-4-Ig prolongs graft survival specifically in young but not in old recipients
Jasper Iske, Germany
07:30 - 08:15 Oral Abstracts Session: Organ Preservation and Reperfusion Injury / Repair
452.1 Empagliflozin, a sodium-glucose cotransporter 2 inhibitor, improves donor heart recovery after prolonged cold storage in an isolated working rat heart model
Jeanette E. Villanueva, Australia
452.2 A single-centre, five-year experience with DCD heart transplantation
Sarah E Scheuer, Australia
452.3 (P-4.59 in Journal) NAPLES study (Normothermic machine perfusion of the liver to enable the sickest first): Preliminary results
Hanns Lembach, United Kingdom
452.4 Enhanced functional recovery of hearts donated after circulatory death (DCD) with ante-mortem heparin.
Ling Gao, Australia
08:15 - 10:00 State-of-the-Art Session: Minimally Invasive Surgery for LDLT
461.1 Small incision donor hepatectomy
Toru Ikegami, Japan
461.2 Pure laparoscopic donor hepatectomy
Kyung-Suk Suh, Korea
461.3 Robotic donor hepatectomy
Dieter Clemens Broering, Saudi Arabia
08:15 - 10:00 State-of-the-Art Session: Recent Breakthroughs in Xenogeneic Tissue and Organ Transplantation
462.1 Heart
Paolo Brenner, Germany
462.3 Islets
Chung-Gyu Park, Korea
462.4 Cornea
Mee Kum Kim, Korea
462.2 Kidney
Kazuhiko Yamada, United States
14:30 - 15:15 Oral Abstracts Session: Kidney Transplantation: Desensitization and other complications
480.4 Rapamycin prevents interstitial fibrosis through decreasing peritubular capillary (PTC) VEGF expression and angiogenesis while inducing glomerular sclerosis and proteinuria through decreasing glomerular VEGF expression
Binnaz Handan Ozdemir, Turkey
480.3 CD8+ T cell senescence is a distinct immunological state that identifies long-term renal transplant recipients at increased risk of future malignancy
Matt J Bottomley DPhil, United Kingdom
480.1 Clazakizumab® (Anti-IL-6) for desensitization of highly-HLA sensitized patients awaiting kidney transplant (NCT03380962)
Ashley Vo, United States
480.2 Clazakizumab (anti-IL-6) induces FoxP3+ Tregs in highly HLA sensitized patients receiving HLAi kidney transplantation (NCT03380962)
Stanley Jordan, United States
15:15 - 17:00 State-of-the-Art Session: Sex as an Immunological Variable
490.3 The role of the X chromosome in organ transplantation
Anette Melk, Germany
490.1 Improved renal ischemia tolerance in females influences kidney transplantation outcomes
Matthew Levine, United States
490.2 Sex as a biological variable
Stefan G. Tullius, United States


Poster Session: Basic and Translational Sciences
P-2.02 B-cell depletion with anti-CD20 mAb exacerbates anti-donor CD4 positive T-Cell responses in highly sensitized transplant model
Asuka Tanaka, Japan
P-2.03 Noninvasive genotyping of donor’s HLA in kidney transplant patients by target capture sequencing
Liu Feng, People's Republic of China
P-2.04 Clinical significance of pretransplant donor-specific HLA antibodies in kidney transplant recipients of hispanic population
Idalia Parra-Avila, Mexico
P-2.05 Female complexity: High ‘natural’ ABO anti-A antibodies and IgG class switch in female vs male mice
Bushra Anjum, Canada
P-2.10 Immune reconstitution after autologous hematopoietic stem cell transplantation in multiple myeloma patients as a basis for early vaccination with T-cell dependent vaccines
Igor Stoma, Belarus
P-2.11 Imbalance favouring follicular helper T cells over IL10+ regulatory B cells is detrimental for the renal allograft
Alberto Utrero-Rico, Spain
P-2.13 Extracellular vesicles from urine as biomarkers of kidney allograft injury: optimization of extracellular vesicle isolation and characterization
Ivana Sedej, Slovenia
P-2.14 Establishment of early warning model of acute rejection in combination with HLA-G 14-bp gene polymorphism, serum KIM-1and OPN
Zhankui Jin, People's Republic of China
P-2.15 Immunosuppression affects circulating follicular regulatory T cells in kidney transplant recipients
Carla C. Baan, Netherlands
P-2.16 The use of dd-cfDNA as a predictive tool for future proteinuria
Thierry Viard, United States
P-2.17 Characterization of an integrative prognostic score for US patients taken from the DART study
Thierry Viard, United States
P-2.18 dd-cfDNA as a risk factor for initiating de-novo donor specific antibodies in heart transplantation
Thierry Viard, United States
P-2.19 Factors influencing background cell-free DNA levels: Implications for donor derived cell-free DNA assessment in transplant patients
Trudy McKanna, United States
P-2.20 Anti-rejection therapy does not eliminate donor-reactive IFN-γ and IL-21 producing cells
Nicole M. van Besouw, Netherlands
P-2.22 Use of dd-cfDNA as a surrogate marker of injury following hypothermic machine perfusion
Thierry Viard, United States
P-2.23 Establishment of early diagnostic model of acute rejection in combination with IL-2, IL-6, TNF-α and IFN-γ
Zhankui Jin, People's Republic of China
P-2.24 Incidence and risk factors of new onset diabetes after solid organ transplantation: Baskent University experience
Didem Turgut, Turkey
P-2.25 Value of dd-cfDNA when considering recipient ethnicity to further to help risk stratify transplant recipients
Thierry Viard, United States
P-2.26 Long-lasting effects of anti-rejection therapy on natural antibodies and alloreactive T cells in kidney transplant patients
Nicole M. van Besouw, Netherlands
P-2.27 Podocyte-specific urinary extracellular vesicles: A novel biomarker for recurrent primary focal segmental glomerulosclerosis after kidney transplantation
Hien Lau, United States
P-2.29 The relationship between myocardial fibrosis and plasma level of galectin-3 in heart transplant recipients underwent acute rejection
Rivada Kurabekova, Russian Federation
P-2.30 Do the blood groups and HLA types have a role in end stage chronic renal failure pathogenesis? A comparative retrospective single-center study
Ugur Musabak, Turkey
P-2.31 Immune signs of accommodation in kidney transplant recipients
Maciej Zieliński, Poland
P-2.32 Spot urine protein excretion during the first year after kidney transplantation associates with allograft rejection phenotype at 1-year surveillance biopsies: An observational national-cohort study
Miha Arnol, Slovenia
P-2.33 The utility of QuantiFERON monitoring based assay in assessing clinical events among kidney transplant recipients
Maisarah Jalalonmuhali, Malaysia
P-2.36 Early post-transplant infusion of ex vivo-expanded autologous polyclonal regulatory T cells (Treg) prolongs kidney allograft survival in nonlymphodepleted, CTLA4Ig-treated rhesus monkeys<span class="uk-margin-small-right" uk-icon="video-camera"></span>
Kazuki Sasaki, United States
P-2.37 IL-21 as a new target for immunosuppressive therapies
Carla C. Baan, Netherlands
P-2.38 The small-molecule BCL6-inhibitor 79-6 suppresses follicular T helper cell differentiation and plasma blast formation
Rens Kraaijeveld, Netherlands
P-2.39 Intra-lymph node delivery of macroparticles loaded with rapamycin in non-human primates
Zahra Habibabady, United States
P-2.40 Clinical-experimental experience with rapamycin in visceral transplantation
Javier Serradilla, Spain
P-2.41 The effects of a novel drug, PQA 18, on small intestinal transplantation
Tasuku Kodama, Japan
P-2.45 Cyclic helix B peptide ameliorates renal fibrosis induced by unilateral ureter obstruction via inhibiting NLRP3 pathway
Cheng Yang, People's Republic of China
P-2.47 The preventive effect of sirolimus on ureteral stricture formation
Sanem Cimen, Turkey
P-2.49 Primate tolerance model demonstrates longer kidney graft survival with the administration of polyclonal ex-vivo expanded Tregs
Karina Bruestle, United States
P-2.50 IL-4 regulates the secretion of IL-10 by human B cells
Griffith Perkins, Australia
P-2.51 Immunomodulation with SA-PDL1 protein on pancreatic islets promotes indefinite graft survival in allogeneic recipients
Esma ESY Yolcu, United States
P-2.53 Anti-IL-6 antibody reduces endothelial mediated pro-inflammatory responses and after binding of HLA-specific DSA to endothelial cells
Nuala Mooney, France
P-2.54 Preclinical study for tolerance induction to liver allografts with rapid immunosuppression withdrawal in Cynomolgus monkeys
Hiroshi Sakai, United States
P-2.55 Strong engagement of Cd137 suppresses graft-versus-host disease through dendritic cells
Sang Jun Park, Korea
P-2.59 The requirement of thymic irradiation for induction of mixed chimerism and renal allograft tolerance in non-human primates
Takayuki Hirose, United States
P-2.60 Experimental evidence on the role of the spleen in graft versus host disease after visceral transplantation
Pablo Stringa, Argentina
P-2.61 Comparison between vitamin C-treated induced-regulatory T cells and conventional induced-regulatory T cells in suppressing heart allograft rejection in either vitamin C-sufficient or vitamin C-deficient conditions
Juhee Hwang, Korea
P-2.62 Advantages of rhesus macaques in a tolerance model for combined bone marrow and kidney transplantation
Karina Bruestle, United States
P-2.63 siRNA gene knockdown with functionalised porous silicon nanoparticles
Sebastian O Stead, Australia
P-2.66 Class II HLA eplet mismatch is related to anti-donor CD4+ T cell response and de novo donor-specific antibody development in kidney transplantation recipient
Hiroaki Yamane, Japan
P-2.70 Changes in phenotype of human CD4+CD25+CD127lo Treg subpopulations after culture with rIL-2 and alloantigen
Nirupama D Verma, Australia
P-2.73 Mobilization of mast cells and regulatory t-cells by tetrahydrobiopterin is associated with prolonged allograft survival
Manuel Maglione, Austria
P-2.82 INT 767 – A novel dual farnesoid-X receptor (FXR) and takeda G-protein-coupled receptor-5 (TGR5) agonist attenuates intestinal ischemia reperfusion injury
Emilio Canovai, Belgium
P-2.84 High-mobility group box 1 protein antagonizes the immunosuppressive capacity and therapeutic effect of mesenchymal stem cells in acute kidney injury
Cheng Yang, People's Republic of China
P-2.85 Mesenchymal stem cell-derived exosomes suppress of NLRP3 inflammasome activation to enhance anti-anoxic ability of porcine islets
Wei Nie, People's Republic of China
P-2.95 A novel rodent model of severe renal ischemia reperfusion injury that better mimics the renal transplant recipient
Ryan Ghita, United Kingdom
P-2.96 Ischemic preconditioning ameliorates renal ischemia-reperfusion injury through activating the Nrf2/HO-1 pathway enhanced autophagy in mice
Jeongkye Hwang, Korea
P-2.99 In-depth assessment of ischemia/reperfusion injury in a murine model of hindlimb transplantation
Franka Messner, Austria
P-2.103 Ischemic preconditioning attenuates renal ischemia-reperfusion injury by TLR4 suppression and eNOS activation
Jeongkye Hwang, Korea
P-2.104 The impact of oxygen free radical scavenger on acute rejection in a histocompatible miniature swine model
Philipp Tratnig-Frankl, United States
P-2.105 The tissue Common Response Module (tCRM) score provides a quantitative objective biopsy score to assess the severity of pancreas transplant rejection
Yvonne Kelly, United States
P-2.107 Increased level of serum cholesterol and apoptosis together induces the development of liver fibrosis and early allograft loss
Binnaz Handan Ozdemir, Turkey
P-2.108 Analyzing interactions between donor endothelium and recipient blood under flow conditions in vitro
Margaret Connolly, United States
P-2.113 Influence of β-Catenin on the proliferation of vascular smooth muscle cells and the development of cardiac allograft vasculopathy in mice
Christian Heim, Germany
P-2.115 Recipient bone marrow Treg; major players in transplant tolerance
Amy Prosser, Australia
P-2.116 High-fibre diet reduces transplant-associated dysbiosis and improves renal allograft survival in a murine model of kidney allograft rejection
Julian Singer, Australia
P-2.119 Gut microbiome dynamics over a course of kidney transplantation: Preliminary results of a pilot study
Igor Stoma, Belarus
P-2.121 Characterization of donor and recipient myeloid cells following congenic and allogeneic liver transplantation
Sarah J Dart, Australia
P-2.122 Preparation of transplantable acellular scleral graft using porcine eye
Kyungmee Park, Korea
P-2.123 Preparation of ultra-thin descemet's membrane graft using decellularized porcine cornea
Kyungmee Park, Korea
P-2.124 NK cell exhaustion facilitates tumor recurrence after liver transplantation via the TLR4 / HLA-E signaling pathway
Xinxiang Yang, People's Republic of China
P-2.126 Assessment of HLA typing performance of Korea Biobank Array for transplantation genome-wide association study in Koreans
Young Jin Kim, Korea
P-2.129 A genome-wide association study identified genetic loci for end-stage renal disease in the Korean population
Young Jin Kim, Korea
P-2.130 Vascular endothelial growth factor (vegf) 936 C/T gene polymorphism in renal transplant recipients: Association with graft rejection and final graft outcome
Manzoor Parry, India
P-2.131 Lymphotoxin beta receptor regulates Treg stability, migration, and function
Vikas Saxena, United States
P-2.133 Liver tissue-resident lymphocytes are significantly heterogeneous, and the original repertoire is not recreated by infiltrating recipient cells
Amy Prosser, Australia
P-2.137 Ischemic and perfused kidney treated with non-cultured adipose-derived regenerative cells increase the immune and regulatory transcriptome
Ryan Ghita, United Kingdom
Poster Session: Cellular and Regenerative Therapies
P-3.06 Generation of stable human induced regulatory T-cells requires optimal rapamycin concentration and TCR stimulation
Juewan Kim, Australia
P-3.11 Small-for-size syndrome is characterized with PD-L1 upregulation in macrophage and blocking PD-L1 accelerates liver regeneration
Ji-Hua Shi, People's Republic of China
P-3.14 Directed differentiation of iPS into imDCs under the action of SN can induce immunoreactivity in vitro
Cuixiang Xu, People's Republic of China
P-3.15 Sinomenine enhances imDC derived from IPS cell-directed differentiation to induce transplant immune hyporesponsiveness in mouse
Cuixiang Xu, People's Republic of China
P-3.03 Cell therapy using CD8+Tregs in human transplantation
Séverine Bézie, France
P-3.10 Bile duct reconstruction using scaffold-free tubular constructs created by a Bio-3D Printer for transplantation
Takashi Hamada, Japan
P-3.13 Visual rehabilitation after penetrating keratoplasty
Leyla Asena, Turkey
P-3.16 Limbal stem cell transplantation for restoration of the ocular surface health in bilateral limbal stem cell deficiency
Dilek Dursun Altinors, Turkey
P-3.01 Mass Cytometry Analysis of the Peripheral Regulatory T cell Compartment after Cellular Therapy in Renal Transplantation
Alaa Alzhrani, United Kingdom
P-3.08 Successful induction of hematopoietic chimerism by MCL-1 and Bcl-2 inhibition without radiation/chemo therapy in nonhuman primates
David Ma, United States
Poster Session: Vascularized Composite Allotransplantation
P-20.01 Subcutaneous implantation of rapamycin impregnated scaffolds demonstrate the potential for localised islet graft immunosuppression
Francis Kette, Australia
P-20.03 Local delivery of FK506 to prevent VCA early acute rejection in a delayed mixed chimerism protocol
Marion P Goutard, United States
Poster Session: Xenotransplantation
P-21.01 Identification of a novel subset of xeno-antigen specific memory CD4+Foxp3+Tregs in islet-xenotransplant tolerance
Leigh Nicholson, Australia
P-21.02 Lack of human thrombomodulin gene expression in life supporting pig-to-baboon cardiac xenotransplantation models may accelerate antibody mediated rejection
Corbin Goerlich, United States
P-21.03 Expression of human thrombomodulin gene on genetically engineered pig hearts prolong cardiac xenograft survivals in non-human primates
Avneesh Singh, United States
P-21.05 Comparison of minimally ischemic cardiac preservation techniques to overcome Perioperative Cardiac Xenograft Dysfunction (pcxd) in life-supporting cardiac xenotransplantation model
Corbin Goerlich, United States
P-21.07 Beta4GalKO reduces anti-non Gal antibody binding in pig-to-baboon and pig-to-human lung transplantation models
Lars Burdorf, United States
P-21.08 Genetic modifications of the porcine genome regulate inflammatory and coagulation responses during ex-vivo porcine liver perfusion with human blood
Nikolaos Serifis, United States
P-21.19 Selection of immunosuppressive drugs for Cord blood derived xenoantigen-stimulated Treg
he xing, People's Republic of China
P-21.11 Microcapsule against hypoxia showed longer graft survival than microcapsule against fibrosis in diabetic mice receiving GalT-KO porcine islet transplantation
Eun Young Lee, Korea
P-21.15 Serological cytokine changes in nonhuman-primate recipients after porcine cardiac xenotransplantation
Hee Jung Kang, Korea
P-21.17 Pre-clinical results of porcine islet re-transplantation after first porcine islet transplantation in rhesus monkeys
Jong-Min Kim, Korea
P-21.20 Selected sequences of porcine elongation factor 1 alpha promoter lead to significant upregulation of target gene responding to human serum induction in porcine cells
Keon B Oh, Korea
P-21.14 CD177 on swine cells suppresses xenogeneic macrophage-mediated cytotoxicity
Pei-Chi Lo, Taiwan
P-21.09 Community perceptions and attitudes towards xenotransplantation in preparation for clinical trials
Luz A Padilla, United States
P-21.10 Survival Benefit of Pig-to-Baboon Liver Xenotransplantation Utilizing Genetically Modified Swine
Taylor Coe, United States
P-21.12 Presence of graft-infiltrating regulatory T cells are associated with long term cardiac xenograft survival in non-human primate
Avneesh Singh, United States
P-21.13 Genetic modifications attenuate but don’t abrogate the sialoadhesin-dependent adhesion of human RBC to porcine macrophages
Kaitlyn Petitpas, United States
P-21.16 New world monkeys as models for testing triple-knockout (TKO) pig red blood cell or skin transplants
Takayuki Yamamoto, United States
P-21.18 Xenogeneic lung perfusion using GalTKO.hCD46 lungs expressing hTFPI and hCD47
Lars Burdorf, United States

WebApp Sponsor

© 2024 TTS 2020